share_log

HC Wainwright & Co. Maintains Buy on Surface Oncology, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on Surface Oncology, Lowers Price Target to $6

HC Wainwright & Co.维持表面肿瘤学买入,将目标价下调至6美元
Benzinga Real-time News ·  2022/11/03 06:18

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Surface Oncology (NASDAQ:SURF) with a Buy and lowers the price target from $8.5 to $6.

HC Wainwright & Co. 分析师Swayampakula Ramakanth维持表面肿瘤学(纳斯达克股票代码:SURF)的买入,并将目标股价从8.5美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发